In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Clinical and echocardiographic outcomes after surgery for severe isolated tricuspid regurgitation

Valvular Heart Diseases

Objective. Few studies have investigated the outcomes after surgical correction of severe isolated tricuspid regurgitation.
Methods. The medical records of 51 consecutive patients (aged 55.8 ± 12.9 years, 25 male) who underwent tricuspid valve surgery at the Asan Medical Center between September 1996 and July 2010 were evaluated retrospectively. All patients had severe isolated tricuspid regurgitation but no significant left-sided cardiac disease or history of heart surgery.

Results. Tricuspid valve repair (n = 37, 72.5%) or replacement (n = 14, 27.5%) was performed. Replacement involved mechanical (n = 4) or bioprosthetic valves (n = 10). One early death occurred (2.0%). During a median follow-up period of 47.4 months (interquartile range, 10.4-61.4 months), 9 late deaths, 3 readmissions for congestive heart failure, 2 heart transplantations, and 1 tricuspid valve reoperation occurred. Overall and event-free survivals at 5 years were 83.5% ± 5.4% and 77.3% ± 6.1%, respectively. In the multivariable Cox regression analysis, preoperative hemoglobin (P = .045), serum bilirubin (P = .008), estimated glomerular filtration rate (P = .045), and systolic right ventricular dimension (P = .047) were significant and independent determinants of clinical outcome. On serial echocardiographic evaluations (median follow-up period, 28.5 months; interquartile range, 18.9-68.7 months), moderate-to-severe tricuspid regurgitation was detected in 21 patients (41%). Severe tricuspid regurgitation after tricuspid valve repair or bioprosthetic valve replacement was a significant predictor of poor event-free survival, even after adjustment for preoperative risk factors (P = .036).

Conclusions. In the present cohort, preoperative anemia, renal/hepatic dysfunction, right ventricular dilatation, and significant postoperative tricuspid regurgitation were associated with poor outcomes. Timely surgery is advisable in patients with severe isolated tricuspid regurgitation before the development of anemia, organ dysfunction, or right ventricular dilatation.

Notes to editor

Journal of thoracic and CV surgery (2013);  146 (2) , 278-284
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.